6978.HK

Immunotech Biopharm Ltd [6978.HK] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

6978.HK Stock Summary

Top 10 Correlated Stocks

6978.HK

In the News

6978.HK Financial details

Company Rating
-
Market Cap
1.74B
Income
-295.9K
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
211
Optionable
No
Shortable
Yes
Earnings
28 Mar 2024
P/E
-5.68
Forward P/E
-
PEG
3.19
P/S
-
P/B
3.94
P/C
-
P/FCF
-7.22
Quick Ratio
0.38
Current Ratio
0.57
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.6
EPS next Y
-
EPS next Q
-
EPS this Y
-5.48%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
1%
SMA50
55.77%
SMA100
106.63%
Inst Own
-
Inst Trans
-
ROA
-40%
ROE
-53%
ROC
-0.42%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.1-5.0
52W High
-18.6%
52W Low
+35.67%
RSI
52.2
Rel Volume
1.31
Avg Volume
44.36K
Volume
58K
Perf Week
-0.73%
Perf Month
-17.78%
Perf Quarter
108.72%
Perf Half Y
117.65%
-
-
-
-
Beta
0.848
-
-
Volatility
0.11%, 0.28%
Prev Close
5.44%
Price
4.07
Change
1.75%

Something similar

Top by Market Cap
MSFT
META
AAPL
JPM
AVGO
Same Sector
BDSI
FBRX
OYST
603108.SS
SBFM
Top Correlated Stocks
CELL.MI
3686.HK
0568.HK
Similar Market Cap
COPX
002743.SZ
EKTAY
YK6B.F
4292.SR

Company Profile

Healthcare Biotechnology
  • Volume Average 44.36K
  • Market Capitalization 1.74B
  • Employee 211
  • CEO Dr. Yu Wang
  • Headquarters Beijing,CN
  • IPO Date 2020-07-10
  • Website https://www.eaal.net

Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People's Republic of China. Its core product is EAL, a multi-target cellular immunotherapy product that is in Phase II clinical trials for the prevention of postsurgical recurrence of liver cancer. The company is also conducting pre-clinical and clinical trial studies for EAL to treat lung cancer, glioma, gastric cancer, and colorectal cancer. In addition, it develops 6B11-OCIK injection that is in Phase I clinical trial for ovarian cancer; CAR-T-19 injection product for B-cell acute lymphoblastic leukaemia; and TCR-T cell series products to treat solid tumors. The company was founded in 2006 and is headquartered in Beijing, the People's Republic of China.